Ty Moore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ty Moore has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Matt Vassar
5 shared publications- Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
5 shared publications - Alyson Haslam
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
4 shared publications - Andriana M. Peña
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
4 shared publications Brooke Gardner
4 shared publications- Chase Ladd
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma
4 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (11) , 9-16
Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study
- 11 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (11) , 9-16
Open AccessCore Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study
- Open Access
- 13 August 2026
- Published by Elsevier in Seminars in Oncology
- Vol. 53 (5) , 152539
Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature
- 13 August 2026
- Published by Elsevier in Seminars in Oncology
- Vol. 53 (5) , 152539
Open AccessAtezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature
- Open Access
- 23 March 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 238, 116686
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
- 23 March 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 238, 116686
Open AccessRisk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
- Open Access
- 13 February 2026
- Published by Elsevier in SSRN Electronic Journal
Core Outcome Set Measures are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study
IntroductionRandomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standardization of PROs in research led to the development of The International Consortium for Health Outcomes Measurement (ICHOM). ICHOM has published literature describing their methodology and development of a breast cancer core outcome set (COS). Our primary aim was to investigate the completeness of reporting within breast cancer clinical trial registries after the publication of the ICHOM breast cancer COS. MethodsA cross-sectional analysis was performed using the ClinicalTrials.gov database. COS information and trial characteristics were extracted from the trial registries in a masked manner. The completeness of reporting of the COS was analyzed. ResultsAfter our final inclusion criteria was applied, our final sample of 237 RCTs were assessed. Systemic therapy was the most commonly reported type of intervention (216/237; 91.1%). The average completeness of reporting was only 28.5% across all of the intervention types, and over three-fourths of the RCTs reported less than half of the COS measures. ConclusionAs PROs and patient-centered healthcare are coming to the forefront of medicine, particularly in oncology, a standardized COS, like ICHOM’s, offers trialists an endorsed resource to thoroughly capture and report the patient perspective in clinical research. We have offered recommendations to improve the reporting of PRO measures to capture within breast cancer RCTs.
- 13 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCore Outcome Set Measures are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study
IntroductionRandomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standardization of PROs in research led to the development of The International Consortium for Health Outcomes Measurement (ICHOM). ICHOM has published literature describing their methodology and development of a breast cancer core outcome set (COS). Our primary aim was to investigate the completeness of reporting within breast cancer clinical trial registries after the publication of the ICHOM breast cancer COS. MethodsA cross-sectional analysis was performed using the ClinicalTrials.gov database. COS information and trial characteristics were extracted from the trial registries in a masked manner. The completeness of reporting of the COS was analyzed. ResultsAfter our final inclusion criteria was applied, our final sample of 237 RCTs were assessed. Systemic therapy was the most commonly reported type of intervention (216/237; 91.1%). The average completeness of reporting was only 28.5% across all of the intervention types, and over three-fourths of the RCTs reported less than half of the COS measures. ConclusionAs PROs and patient-centered healthcare are coming to the forefront of medicine, particularly in oncology, a standardized COS, like ICHOM’s, offers trialists an endorsed resource to thoroughly capture and report the patient perspective in clinical research. We have offered recommendations to improve the reporting of PRO measures to capture within breast cancer RCTs.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1: Flow diagram for study inclusion.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1: Flow diagram for study inclusion.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1701-1711
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1701-1711
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 3 November 2023
- Published by SAGE Publications in Plastic Surgery
- Vol. 33 (2) , 338-347
Health Inequities in the Epidemiology, Diagnosis, Treatment, and Outcomes of Plastic Surgery: A Scoping Review
Background: Plastic surgery is routinely sought after for the treatment of breast cancer, cleft lip and palate, and gender-affirming care. Inequities exist in plastic surgery in regard to the epidemiology, diagnosis, treatment, and outcomes experienced by patients. The purpose of our scoping review was to (1) outline current literature addressing health inequities in plastic surgery and (2) draw attention to the gaps in this literature. Methods: This scoping review was developed following guidelines from the Joanna Briggs Institute and PRISMA extension for scoping reviews. An initial search of MEDLINE (via PubMed), Ovid Embase, Cochrane Database of Systematic Reviews, and Scopus databases was performed to locate published articles on health inequities in plastic surgery. Articles had to address at least one of the National Institutes of Health's inequity groups we examined. Results: After reviewing full text, 153 studies were included in our final sample. We found race/ethnicity (94/153) and age (90/153) to be the 2 most commonly evaluated inequities in the scoping review. We discovered that patient populations that were older had public or no insurance and/or were in historically marginalized racial/ethnic groups were often less likely to be offered plastic surgery treatments. Conclusion: This scoping review describes the current literature on health inequities in plastic surgery and highlights gaps in the literature that warrant further research. We found significant findings regarding how vulnerable patient populations are affected by health inequities. Research should be conducted to investigate these inequities more thoroughly and discover the best solutions to bridge the gaps in providing equitable care.
- 3 November 2023
- Published by SAGE Publications in Plastic Surgery
- Vol. 33 (2) , 338-347
Health Inequities in the Epidemiology, Diagnosis, Treatment, and Outcomes of Plastic Surgery: A Scoping Review
Background: Plastic surgery is routinely sought after for the treatment of breast cancer, cleft lip and palate, and gender-affirming care. Inequities exist in plastic surgery in regard to the epidemiology, diagnosis, treatment, and outcomes experienced by patients. The purpose of our scoping review was to (1) outline current literature addressing health inequities in plastic surgery and (2) draw attention to the gaps in this literature. Methods: This scoping review was developed following guidelines from the Joanna Briggs Institute and PRISMA extension for scoping reviews. An initial search of MEDLINE (via PubMed), Ovid Embase, Cochrane Database of Systematic Reviews, and Scopus databases was performed to locate published articles on health inequities in plastic surgery. Articles had to address at least one of the National Institutes of Health's inequity groups we examined. Results: After reviewing full text, 153 studies were included in our final sample. We found race/ethnicity (94/153) and age (90/153) to be the 2 most commonly evaluated inequities in the scoping review. We discovered that patient populations that were older had public or no insurance and/or were in historically marginalized racial/ethnic groups were often less likely to be offered plastic surgery treatments. Conclusion: This scoping review describes the current literature on health inequities in plastic surgery and highlights gaps in the literature that warrant further research. We found significant findings regarding how vulnerable patient populations are affected by health inequities. Research should be conducted to investigate these inequities more thoroughly and discover the best solutions to bridge the gaps in providing equitable care.
- Open Access
- 4 April 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (3) , e1069
Discontinuation and nonpublication analysis of chronic pain randomized controlled trials
Introduction: The primary objective of this cross-sectional analysis is to evaluate rates of discontinuation and nonpublication of Randomized controlled trials (RCTs) of therapeutic interventions to treat chronic pain. Methods: Using ClinicalTrials.gov, a sample was obtained which included clinical trials pertaining to chronic pain. Trials were analyzed for publication status and completion status of each trial. If information was unavailable on the trial registry database, or could not be allocated through a systematic search, the corresponding trialist was contacted and data points were gathered. Results: In our final analysis of the 408 RCTs, we found that 281 (68.9%) were published in a peer-reviewed journal and 127 (31.1%) were unpublished trials. Of 112 discontinued trials, 59 (52.7%) reached publication. In addition, 221 of 296 completed trials (74.7%) were published, and 75 (25.3%) remained unpublished after trial completion. The most common listed reason for trial discontinuation was administrative recommendations (41 of 71 trials [57.7%]), while not receiving an email reply to our standardized email from the corresponding trialist was the most common result for trial nonpublication (49 of 88 trials [55.7%]). Clinical trials funded by nonindustry sponsors were more likely to reach publication than industry-funded clinical trials (unadjusted odds ratio 1.86 [95% CI, 1.18–2.95]; adjusted odds ratio 3.01 [95% CI, 1.76–5.14]). Conclusion: The rate of discontinuation of RCTs involving patients with chronic pain is concerning. Chronic pain affects many patients; thus, the importance of having quality data from clinical trials cannot be overstated. Our study indicates that chronic pain RCTs are frequently discontinued and their findings often go unpublished — all of which could provide crucial information to providers and patients regarding the treatment of chronic pain. We offer suggestions to enhance chronic pain RCT completion, thereby reducing the waste of resources in chronic pain research.
- 4 April 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (3) , e1069
Open AccessDiscontinuation and nonpublication analysis of chronic pain randomized controlled trials
Introduction: The primary objective of this cross-sectional analysis is to evaluate rates of discontinuation and nonpublication of Randomized controlled trials (RCTs) of therapeutic interventions to treat chronic pain. Methods: Using ClinicalTrials.gov, a sample was obtained which included clinical trials pertaining to chronic pain. Trials were analyzed for publication status and completion status of each trial. If information was unavailable on the trial registry database, or could not be allocated through a systematic search, the corresponding trialist was contacted and data points were gathered. Results: In our final analysis of the 408 RCTs, we found that 281 (68.9%) were published in a peer-reviewed journal and 127 (31.1%) were unpublished trials. Of 112 discontinued trials, 59 (52.7%) reached publication. In addition, 221 of 296 completed trials (74.7%) were published, and 75 (25.3%) remained unpublished after trial completion. The most common listed reason for trial discontinuation was administrative recommendations (41 of 71 trials [57.7%]), while not receiving an email reply to our standardized email from the corresponding trialist was the most common result for trial nonpublication (49 of 88 trials [55.7%]). Clinical trials funded by nonindustry sponsors were more likely to reach publication than industry-funded clinical trials (unadjusted odds ratio 1.86 [95% CI, 1.18–2.95]; adjusted odds ratio 3.01 [95% CI, 1.76–5.14]). Conclusion: The rate of discontinuation of RCTs involving patients with chronic pain is concerning. Chronic pain affects many patients; thus, the importance of having quality data from clinical trials cannot be overstated. Our study indicates that chronic pain RCTs are frequently discontinued and their findings often go unpublished — all of which could provide crucial information to providers and patients regarding the treatment of chronic pain. We offer suggestions to enhance chronic pain RCT completion, thereby reducing the waste of resources in chronic pain research.